Literature analysis of atypical fractures associated with denosumab
- VernacularTitle:地舒单抗相关非典型骨折的文献分析
- Author:
Yongfei ZHENG
1
;
Huina LIU
1
Author Information
1. Dept. of Pharmacy，Zhengzhou Orthopaedic Hospital，Zhengzhou 450052，China
- Publication Type:Journal Article
- Keywords:
denosumab;
atypical fractures;
osteoporosis;
literature analysis
- From:
China Pharmacy
2023;34(16):1999-2002
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the characteristics and regularity of denosumab-associated atypical fractures （AF）， so as to provide references for clinical rational use of drugs. METHODS The case reports of AF related to denosumab were retrieved from PubMed， Web of Science， CNKI， Wanfang data and VIP databases， and the reports were descriptively analyzed. RESULTS A total of 19 references were retrieved， including 20 patients. There were 3 males and 17 females， with an average age of （69.80± 15.39） years. Among 20 patients， primary diseases of 14 patients were osteoporosis， and 6 cases were malignant tumor bone metastasis and giant cell tumor of bone. The occurrence time of AF ranged from 3 to 132 months after the administration of denosumab， with an average of （42.14±29.49） months. Fourteen cases had prodromal symptoms before AF. There were 3 cases of ulna fractures， and the remaining 17 cases were femoral fractures. The vast majority of patients recovered well after discontinuing medication and undergoing surgical fixation， but some patients experienced delayed fracture healing. CONCLUSIONS Long-term use of denosumab should be vigilant against AF. When patients experience prodromal symptoms such as thigh， groin， hip joint and forearm pain， they should seek medical attention in a timely manner to ensure medication safety.
